The therapeutic potential of mesenchymal stromal cell secretome in treating spontaneous chronic corneal epithelial defects in dogs.
Casado-Santos A., González-Cubero E., García-Rodríguez MB., Carrera-Serna Á., González-Fernández ML., Villar-Suárez V.
Animal Study, published in Res Vet Sci (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Res Vet Sci (2025)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 39923345
- DOI
- 10.1016/j.rvsc.2025.105559
Abstract (original English)
Corneal ulcers in dogs pose a significant challenge in veterinary ophthalmology, often leading to prolonged visual impairment and discomfort. This study aimed to assess the efficacy of adipose tissue-derived mesenchymal stromal cell (ASCs) secretome as a treatment for complicated corneal ulcers in dogs. Ten dogs with spontaneous chronic corneal epithelial defects, were treated with topical application of ASC secretome eye drops. Our results showed that secretome therapy facilitated complete healing of all corneal ulcers within 4 weeks, with an average healing time of 1.2 weeks. Notably, secretome treatment was effective even in cases that had previously failed to respond to conventional therapies. Clinical signs such as blepharospasm, conjunctival hyperemia, and photophobia were alleviated promptly following secretome administration. Secretome therapy was well-tolerated, with no adverse reactions reported, further supporting its safety profile. The findings suggest that ASC secretome represents a promising cell-free and minimally invasive therapeutic approach for the treatment of complicated corneal ulcers in dogs.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.